文献速递血栓与止血

血友病新型非因子治疗中的血栓与出血平衡

Thrombosis and novel hemophilia therapies: the fine line between clotting and bleeding.
PubMed 文献 · Blood Adv · 2021-01-01

本文讨论血友病新型非因子疗法(emicizumab、fitusiran、concizumab)在突破性出血时联用其他止血药相关的血栓事件,指出目前缺乏精确的体内止血机制模型,难以预测这些药物与凝血系统其他干预的相互作用。

要点

  • 非因子疗法在突破性出血时联用其他止血药可发生血栓事件。
  • 三种药物均提高血浆凝血酶峰值并降低出血率。
  • 目前难以精确预测新药与凝血系统其他干预的相互作用。

核心结论

  • 非因子疗法相关血栓事件主要见于突破性出血时联用其他止血药的患者。
  • 目前尚无良好的机制模型精确解释这些疗法在体内的止血作用。

研究设计与样本

  • 本文为视频综述,讨论三种非因子产品(emicizumab、fitusiran、concizumab)相关血栓并发症。

主要发现

  • Emicizumab为双特异性抗体,模拟凝血因子VIII的辅因子活性。
  • Fitusiran为小干扰RNA,敲低抗凝血酶合成。
  • Concizumab为抗体,阻断组织因子途径抑制物对凝血因子Xa的抑制。
  • 后两者基于通过降低抗凝活性补偿促凝缺陷以「再平衡」止血的 premise。
  • 三种方法均提高治疗对象血浆检测中的凝血酶峰值水平,并降低有或无抑制物个体的出血率。

临床怎么用

  • 使用非因子疗法患者发生突破性出血时,联用其他止血药需警惕血栓事件。
  • 目前难以预测这些新药与凝血系统其他扰动或治疗操作的相互作用。

局限性

  • 目前尚无良好的机制模型精确解释这些疗法在体内的止血作用。
  • 止血效果不仅取决于产生的活性凝血酶总量,还取决于凝血酶生成的调控方式。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The availability of novel nonfactor therapeutics is revolutionizing the management of hemophilia in individuals with inhibitory antibodies, as well as making prophylaxis more convenient even in the absence of inhibitors. Unfortunately, the use of these products has been associated with thrombotic events that are not typically seen with factor replacement. These are primarily seen when a patient on a nonfactor therapy experiences breakthrough bleeding and concomitantly receives another hemostatic agent. This video addresses thrombotic complication in 3 nonfactor products: (1) emicizumab, a bispecific antibody that mimics the cofactor activity of factor VIII; (2) fitusiran, an small interfering RNA that knocks down synthesis of antithrombin; and (3) concizumab, an antibody that blocks inhibition of factor Xa by tissue factor pathway inhibitor. The latter 2 agents were developed on the premise that hemostasis in hemophilia could be "rebalanced" by reducing the levels of anticoagulant activity to compensate for the defect in procoagulant activity. Each of these approaches increases peak levels of thrombin achieved in assays on plasma from treated subjects and reduces bleeding rates in individuals with or without inhibitors. However, we do not yet have a good mechanistic model for precisely how these approaches affect hemostasis in vivo. It is not only the total amount of active thrombin produced that determines the effectiveness of hemostasis but also how thrombin generation is regulated. Therefore, it is currently difficult to predict how these new agents will interact with other perturbations or therapeutic manipulations of the coagulation system.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Hoffman M. Thrombosis and novel hemophilia therapies: the fine line between clotting and bleeding. Blood Adv. 2021. PMID: 34581771. doi:10.1182/bloodadvances.2021004802C

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。